Secondary Outcomes Absolute RPF decreased significantly, by 15.83 ± 39.98 ml/min, ( P = 0.041) during dapagliflozin treatment, whereas the 7.94 ± 20.73 ml/min per 1.73 m 2 reduction in normalized RPF was borderline significant ( P = 0.052).
The highly significant 1- and 6-week increase in glucosuria and glucose fractional clearance achieved by dapagliflozin while the placebo had no appreciable effects, confirms that SGLT2 inhibitors exert their biological effect even in patients with nondiabetic CKD and provides novel evidence that this effect can be extended to patients with severe renal insufficiency.